



Market Announcement

25 July 2022

MedAdvisor Limited (ASX: MDR) – Trading Halt (2)

Description

The securities of MedAdvisor Limited ('MDR') will be placed in trading halt at the request of MDR, pending it releasing an announcement regarding the outcome of the institutional component of the accelerated entitlement offer. Unless ASX decides otherwise, the securities will remain in trading halt until the commencement of normal trading on Wednesday, 27 July 2022.

Issued by

Sean Maloney

Senior Adviser, Listings Compliance (Perth)

25 July 2022

Barbara Lim
Listings Compliance (Perth)
ASX Limited
Level 40, Central Park
152-158 St Georges Terrace
Perth WA 6000

Via e-mail

Cc: tradinghaltspert@asx.com.au

Dear Ms Barbara Lim

MedAdvisor Limited (ASX:MDR) – Request for Trading Halt

Pursuant to ASX Listing Rule 17.1, MedAdvisor Limited ACN 145 327 617 (**Company**) requests that the ASX grants a trading halt with respect to the Company's shares.


The Company provides the following information regarding this request:

1. The reason for the trading halt is that the Company intends to make an announcement regarding a material acquisition and a capital raising to be undertaken by way of an accelerated, pro rata non-renounceable entitlement offer accompanied (**Offer**). The trading halt is required to enable the institutional component of the Offer to be conducted in an orderly manner on ASX.
2. The Company requests that the trading halt continues until the earliest of:
 - a. such time as the Company makes an announcement to the market in relation to the outcome of the institutional component of the Offer; and
 - b. the open of trading on Wednesday, 27 July 2022.
3. The Company expects that the ASX announcement about the acquisition and the Offer will be made before 10.00am today and a further announcement about the outcome of the institutional component of the Offer as soon as possible, and in any event, prior to the open of trading on Wednesday, 27 July 2022.
4. The Company considers that the trading halt are necessary as otherwise trading in the Company's shares would continue on an uninformed basis.

5. The Company is not aware of any reason why a trading halt should not be granted or any other information necessary to inform the market about the requested trading halt or voluntary suspension.

If you have any queries, please do not hesitate to contact me.

Yours sincerely



Naomi Lawrie

General Counsel and Company Secretary
MedAdvisor Limited